Cargando…
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
IMPORTANCE: Patients with cancer have an increased risk of severe disease and mortality from COVID-19, as the disease and antineoplastic therapy cause reduced vaccine immunogenicity. Booster doses have been proposed to enhance protection, and efficacy data are emerging from several studies. OBJECTIV...
Autores principales: | Mai, Aaron Shengting, Lee, Ainsley Ryan Yan Bin, Tay, Ryan Yong Kiat, Shapiro, Lauren, Thakkar, Astha, Halmos, Balazs, Grinshpun, Albert, Herishanu, Yair, Benjamini, Ohad, Tadmor, Tamar, Shroff, Rachna T., LaFleur, Bonnie J., Bhattacharya, Deepta, Peng, Siyu, Tey, Jeremy, Lee, Soo Chin, Chai, Louis Yi Ann, Soon, Yu Yang, Sundar, Raghav, Lee, Matilda Xinwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163022/ https://www.ncbi.nlm.nih.gov/pubmed/35753213 http://dx.doi.org/10.1016/j.ejca.2022.05.029 |
Ejemplares similares
-
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022) -
Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021) -
Clinical efficacy and Long-term Immunogenicity of early triple dose COVID-19 mRNA vaccine in cancer patients
por: Li, Jiaqi, et al.
Publicado: (2023) -
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
por: Lee, Ainsley Ryan Yan Bin, et al.
Publicado: (2022) -
Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
por: Benjamini, Ohad, et al.
Publicado: (2022)